Founded in 2014 as a subsidiary of Kelun-Biotech, KLUS Pharma is committed to the discovery and development of innovative biotherapeutics. Our top priority is to address the unmet needs of patients suffering from cancer, cardiovascular disease, autoimmune disease, and other severe disorders due to the lack of effective treatment options. Utilizing our innovative technology platforms for monoclonal antibodies, bispecific antibodies, and Antibody-Drug Conjugates (ADCs), we have advanced multiple biologic programs into the clinical stage to treat these debilitating conditions.
KLUS Pharma has streamlined antibody discovery and engineering capabilities, which enable a seamless transition from target discovery to product development. Our team of industry experts in immuno-oncology, immunology, and cardiology, can rapidly advance biological drug candidates from bench to market. KLUS Pharma has identified and assessed dozens of therapeutic targets and is currently conducting preclinical and clinical studies for more than 10 antibody-based therapeutics.
Our company is focused on addressing the needs of patients who lack effective treatment options and aims to combat life-threatening diseases with the discovery and development of novel and safer antibody-based therapeutics.
SKB264 (TROP2 ADC) Phase 1 trial initiated in the US
A166 (HER2 ADC) Phase 1 trial initiated in the US
Department of Translational Medicine established
Department of Biologics R&D established
Department of Clinical Research established
Department of Business Development established
KLUS Pharma founded